CD274 and hepatocellular carcinoma: In hepatocellular carcinoma, Hh pathway inhibition with vismodegib or genetic depletion results in immunologic changes, including reduced PD-L1 expression, improved cytotoxic function of T cells and improved ICIs therapeutic efficiency (94, 96).